The latest price of lorlatinib (lorlatinib) targeted drug in 2024

Lorlatinib (Lolatinib) is an oral, small molecule targeted drug used to treat a specific type of non-small cell lung cancer (NSCLC), namely < /span>ALKpositive and ROS1positiveNSCLC. It is a third-generation ALK inhibitor that inhibits the activity of ALK, ROS1 and the neuroepithelial growth factor receptor (EGFR) family. Lorlatinib (lorlatinib) is used to treat patients who have failed or are intolerant to other ALK inhibitors and ROS1 inhibitors.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For specific medical insurance reimbursement prices, please consult the local hospital pharmacy. There are lorlatinib (lorlatinib) original drugs and cheaper generic drugs abroad. The cheaper ones are the original drugs from Turkey, which cost more than 7,000 yuan, and the original drugs from Hong Kong, China, which cost about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about more than 1,000 yuan to several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.

The mechanism of action of lorlatinib is mainly by inhibiting the ALK and ROS1 proteins in tumor cells, thereby blocking the signaling pathways of these proteins and inhibiting the growth and division of tumor cells. Compared with the first and second generation ALK inhibitors, lorlatinib (lorlatinib) has higher targeting and inhibitory power, and can effectively overcome the resistance of tumor cells to previous therapeutic drugs.

Clinical trials have shown thatlorlatinib has shown good efficacy in the treatment of ALK and ROS1 positive NSCLC patients. In a multicenter clinical trial, lorlatinib treated ALKpositive patientsNSCLCThe overall response rate for patients has reached 60% and sustained remission for several years has been observed in some patients. In addition, the toxic and side effects of lorlatinib are relatively mild, mainly including visual disturbances, gastrointestinal reactions and liver function abnormalities, etc., which can generally be managed by adjusting the dose or symptomatic treatment.

However, it should be noted thatlorlatinib is not suitable for all patients withALK and ROS1positiveNSCLC. Before use, doctors usually perform genetic testing on patients to determine whether they are candidates for treatment with the drug. In addition, some patients may develop drug resistance or adverse drug reactions during use, so regular monitoring of the condition and adjustments are required.